Koh K K, Horne M K, Csako G, Waclawiw M A, Cannon R O
Cardiology Branch and the Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1650, USA.
Am J Cardiol. 1999 Feb 1;83(3):466-9, A10. doi: 10.1016/s0002-9149(98)00891-1.
To determine whether enhanced fibrinolysis is a primary effect of estrogen or is secondary to activation of coagulation, we measured hemostatic factors before and after conjugated equine estrogen 0.625 mg/day for 1 month in 9 postmenopausal women. We found that potentiation of fibrinolysis is a primary effect of conjugated equine estrogens at this commonly used dosage in healthy postmenopausal women.
